Category: Pharma
EU HTA Is Changing European Market Access: Why Early Evidence Planning Is Now Essential
EU HTA Is Changing European Market Access: Why Early Evidence Planning Is Now Essential The European pharmaceutical industry is entering a new era. With the implementation of the European Union Health Technology Assessment (EU HTA) Regulation, companies must rethink how they generate clinical evidence, align cross-functional teams, and prepare for successful market access across Europe.…
Why Pharma Companies Should Stress-Test Their Market Access Strategy Before EU HTA Submission
Why Pharma Companies Should Stress-Test Their Market Access Strategy Before EU HTA Submission How pre-submission evidence reviews are becoming the next competitive advantage for pharmaceutical and biotech companies in Europe. The pharmaceutical industry has entered a new era of evidence generation. For years, achieving regulatory approval was considered the biggest milestone on the path to…
From Evidence Generation to Market Access: Why Integrated Evidence Planning Is Pharma’s Competitive Advantage Under EU HTA
From Evidence Generation to Market Access: Why Integrated Evidence Planning Is Becoming Pharma’s Competitive Advantage Under EU HTA How cross-functional collaboration, Real-World Evidence, AI, and early planning are reshaping successful market access strategies across Europe. The European pharmaceutical landscape is changing rapidly. Over the past year, discussions around the EU Health Technology Assessment (HTA) Regulation…
What Can We Learn from the First Three EU Joint Clinical Assessment (JCA) Reports?
What Can We Learn from the First Three EU Joint Clinical Assessment (JCA) Reports? The European Union’s Health Technology Assessment (HTA) Regulation has entered a new era. In just a few months, the European Commission has published the first three official Joint Clinical Assessment (JCA) reports, providing pharmaceutical companies with the clearest indication yet of…
Evidence Generation Is No Longer Enough: Why Evidence Prioritisation Is Pharma’s Next Competitive Advantage
Evidence Generation Is No Longer Enough: Why Evidence Prioritisation Is Pharma’s Next Competitive Advantage in the EU HTA Era The Industry Has Moved Beyond Generating More Evidence For years, pharmaceutical innovation has focused on answering one fundamental question: “Do we have enough evidence to secure regulatory approval?” Today, that question has evolved. Across Europe, Market…
Overcoming ‘PICO Anxiety’: How Biopharma Can Master the New European HTA Era
Overcoming ‘PICO Anxiety’: How Biopharma Can Master the New European HTA Era The European pharmaceutical market access landscape is entering a new phase. With the implementation of the European Union Health Technology Assessment (EU HTA) Regulation, Joint Clinical Assessments (JCA) are becoming an integral part of evidence planning for eligible medicines across Europe. As mandatory…
EU HTA Joint Clinical Assessments: 7 Critical Pharma Mistakes
EU HTA Joint Clinical Assessments (JCA): The 7 Critical Mistakes Pharma Companies Must Avoid Before Their First Submission The European healthcare landscape is undergoing one of the most significant transformations in decades. With the implementation of the European Union Health Technology Assessment (EU HTA) Regulation and the introduction of Joint Clinical Assessments (JCA), pharmaceutical and…
DARWIN EU 2.0 & JCA PICO Strategy: Streamlining Multi-State RWE
Mastering DARWIN EU 2.0 Interoperability for JCA Compliance: The Technical Blueprint for Multi-State Real-World Evidence The European market access landscape is undergoing its most profound structural disruption since the centralization of regulatory approvals. The rollout of the European Union Health Technology Assessment (EU-HTA) regulation has effectively shifted the goalposts for pharmaceutical manufacturers. No longer can…
Regulatory-Grade AI and Living Evidence
Why Regulatory-Grade AI & Living Evidence Are Replacing Traditional RWE Models in Pharma A Turning Point for Real-World Evidence in Pharma Real-World Evidence (RWE) has become a cornerstone of pharmaceutical decision-making. Regulators, HTA bodies, and payers increasingly rely on RWE to support approvals, reimbursement decisions, and post-market monitoring. However, as expectations rise, traditional RWE models…
From Unstructured Data to Regulatory Decisions
From Unstructured Data to Regulatory Decisions: How AI Is Redefining Real-World Evidence The New Reality of Real-World Evidence (RWE) Real-World Evidence (RWE) has moved from the periphery of healthcare decision-making to the very center of regulatory, payer, and market access strategies. As regulators, HTA bodies, and healthcare systems increasingly rely on RWE to complement clinical…
